New scientific statement outlines recommendations for diagnosing, managing cerebral venous thrombosis

A new scientific statement from the American Heart Association emphasizes the need to increase patients’ and physicians’ awareness of cerebral venous thrombosis (CVT) to improve the recognition of this condition and initiate prompt medical treatment.

Eli Lilly’s Zepbound available in two vials for self-pay patients

Zepbound is prescribed for adults with obesity or those overweight with weight-related medical issues. Credit: Ciara Kimsey/Shutterstock. Eli Lilly and Company has announced the availability

August 28, 2024

Sandoz inks $275M settlement in generic antitrust litigation

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

December 18, 2024

TOS members unveil new research about anti-obesity medications at ADA annual meeting

Multiple members of The Obesity Society (TOS) unveiled new research about several anti-obesity medications in development at this year’s annual meeting of the American Diabetes

June 29, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.